KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Other Non Operating Income (2018 - 2025)

Esperion Therapeutics' Other Non Operating Income history spans 8 years, with the latest figure at $3.5 million for Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 94.3% year-over-year to $3.5 million; the TTM value through Dec 2025 reached $5.9 million, down 91.11%, while the annual FY2025 figure was $3.5 million, 56.49% down from the prior year.
  • Other Non Operating Income reached $3.5 million in Q4 2025 per ESPR's latest filing, up from $677000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $61.2 million in Q4 2024 to a low of -$1.3 million in Q4 2022.
  • Average Other Non Operating Income over 5 years is $4.7 million, with a median of $874500.0 recorded in 2025.
  • Peak YoY movement for Other Non Operating Income: surged 16312.5% in 2021, then crashed 132.93% in 2022.
  • A 5-year view of Other Non Operating Income shows it stood at $3.9 million in 2021, then plummeted by 132.93% to -$1.3 million in 2022, then surged by 507.94% to $5.3 million in 2023, then soared by 1057.1% to $61.2 million in 2024, then crashed by 94.3% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Other Non Operating Income are $3.5 million (Q4 2025), $677000.0 (Q3 2025), and $666000.0 (Q2 2025).